U.S. markets closed
  • S&P 500

    +73.47 (+1.95%)
  • Dow 30

    +572.16 (+1.85%)
  • Nasdaq

    +196.68 (+1.55%)
  • Russell 2000

    +45.29 (+2.11%)
  • Crude Oil

    +2.45 (+3.84%)
  • Gold

    -2.50 (-0.15%)
  • Silver

    -0.17 (-0.65%)

    -0.0063 (-0.52%)
  • 10-Yr Bond

    +0.0040 (+0.26%)

    -0.0060 (-0.43%)

    +0.3840 (+0.36%)

    +851.85 (+1.75%)
  • CMC Crypto 200

    +39.75 (+4.21%)
  • FTSE 100

    -20.36 (-0.31%)
  • Nikkei 225

    -65.78 (-0.23%)

Notice of Lead Plaintiff Deadline for Shareholders in the Allakos Inc. Securities Class Action Lawsuit

  • Oops!
    Something went wrong.
    Please try again later.
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Robbins Geller Rudman & Dowd LLP announces that the lead plaintiff motion deadline in the Allakos securities class action lawsuit is May 11, 2020. A securities class action lawsuit was filed in the Northern District of California on behalf of purchasers of Allakos Inc. (NASDAQ: ALLK) securities between August 5, 2019 and December 17, 2019 (the "Class Period") charging Allakos and certain of its officers with violations of the Securities Exchange Act of 1934. The case is captioned Kim v. Allakos Inc., No. 20-cv-01720, and is assigned to Judge Jeffrey S. White.

The Allakos securities class action lawsuit alleges that defendants made false and misleading statements and/or failed to disclose adverse information regarding the Phase 2 clinical trial of one of the Company’s drugs in development, AK002, including that the trial was poorly designed and not well-controlled, that Allakos had cherry-picked timeframes to engineer results and used superficial endpoints relative to FDA guidance, that Allakos had misrepresented the number of adverse incidents that occurred and failed to report key data, and that, as a result, defendants’ public statements regarding the Company’s business and prospects were materially false and misleading at all relevant times.

The Private Securities Litigation Reform Act of 1995 permits any investor who purchased Allakos securities during the Class Period to seek appointment as lead plaintiff in the Allakos securities class action lawsuit. A lead plaintiff acts on behalf of all other class members in directing the Allakos securities class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Allakos securities class action lawsuit. An investor’s ability to share in any potential future recovery of the Allakos securities class action lawsuit is not dependent upon serving as lead plaintiff. If you wish to serve as lead plaintiff of the Allakos securities class action lawsuit or have questions concerning your rights regarding the Allakos securities class action lawsuit, please visit our website by clicking here or contact J.C. Sanchez at 800/449-4900 or 619/231-1058, or via e-mail at jsanchez@rgrdlaw.com. Lead plaintiff motions for the Allakos securities class action lawsuit must be filed with the court no later than May 11, 2020.

Allakos is a clinical stage biopharmaceutical company that focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. Allakos is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. On August 5, 2019, Allakos issued a press release announcing that AK002 had met all pre-specified primary and secondary endpoints in its Phase 2 clinical trial (the "ENIGMA Trial").

On December 18, 2019, Seligman Investments published a report entitled "A Suspect Biotech with a Phase 2 Farce, Incredulous Trial Investigators, and Warning Signs of Potential Fraud." The report identified several concerns regarding the ENIGMA Trial, including that Allakos’s role in running the study itself rendered the purportedly randomized and double-blind study essentially un-blinded; that Allakos allowed steroid use in a liberal, widespread manner, rendering the results utterly flawed and compromised; that Allakos’s representation of only one drug-related serious adverse event conflicted with numerous Facebook posts by trial participants; and that Allakos’s endpoints were superficial relative to competing trials and FDA guidance. On this news, the price of Allakos’s stock fell by nearly 10%.

Robbins Geller Rudman & Dowd LLP is one of the world’s leading law firms representing investors in securities litigation. With 200 lawyers in 9 offices, Robbins Geller has obtained many of the largest securities class action recoveries in history. For seven consecutive years, ISS Securities Class Action Services has ranked the Firm in its annual SCAS Top 50 Report as one of the top law firms in the world in both amount recovered for shareholders and total number of class action settlements. Robbins Geller attorneys have helped shape the securities laws and have recovered tens of billions of dollars on behalf of aggrieved victims. Beyond securing financial recoveries for defrauded investors, Robbins Geller also specializes in implementing corporate governance reforms, helping to improve the financial markets for investors worldwide. Robbins Geller attorneys are consistently recognized by courts, professional organizations, and the media as leading lawyers in the industry. Please visit http://www.rgrdlaw.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200413005023/en/


Robbins Geller Rudman & Dowd LLP
J.C. Sanchez, 800-449-4900